| Detected | Trial | Change |
|---|---|---|
| 2026-05-19 | NCT03370263 BENLYSTA® Special Drug Use Investigation |
date change Primary completion moved earlier: 2025-09-26 -> 2025-07-31 |
| 2026-05-19 | NCT03370263 BENLYSTA® Special Drug Use Investigation |
date change Completion moved earlier: 2025-09-26 -> 2025-07-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06411249 | A Study Describing the Efficacy and Safety of Belimumab Administered in Adult… | Systemic Lupus Erythematosus | Recruiting |
| Phase 3 | |||
| NCT06572384 | A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease… | Lung Diseases, Interstitial | Recruiting |
| Phase 2/3 | |||
| NCT05878717 | A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis… | Systemic Sclerosis Associated Interstitial Lung Disease | Recruiting |
| Phase 2 | |||
| NCT07340463 | The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in… | Systemic Lupus Erythematosus (SLE) | Recruiting |
| NCT03844061 | Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous… | Systemic Sclerosis | Recruiting |
| NCT06381453 | Belimumab in Autoimmune Hepatitis | Autoimmune Hepatitis | Recruiting |
| NCT03949855 | Belimumab With Rituximab for Primary Membranous Nephropathy | Membranous Nephropathy | Recruiting |
| Phase 1 | |||
| NCT04097561 | Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe) | Idiopathic CD4 Lymphopenia | Recruiting |
| NCT06576271 | A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE)… | Systemic Lupus Erythematosus | Recruiting |